Characteristic | 16–25 OR (95% CI p value) | 26–35 OR (95% CI p value) | 36–45 OR (95% CI p value) | 46–55 OR (95% CI p value) |
---|---|---|---|---|
Age per 5 years | 1.39 (1.14–1.69, < 0.01) | 1.21 (1.02–1.43, 0.02) | – | – |
Black | 1.41 (1.04–1.91, 0.02) | – | – | – |
Other race | – | – | – | – |
Diabetes | 1.89 (1.09–3.29, 0.02) | 1.86 (1.20–2.89, < 0.01) | 1.52 (1.14–2.02, 0.01) | 1.55 (1.28–1.85, 0.01) |
Fluid balance > 5% | – | – | – | – |
Malignancy | – | – | – | – |
Hypertension | – | – | – | – |
Cardiac disease | – | 3.75 (2.23–6.29, < 0.01) | 2.00 (1.47–2.72, < 0.01) | 1.36 (1.12–1.64, 0.01) |
Chronic kidney disease | – | – | – | – |
Surgical admission | 1.79 (1.44–2.23, < 0.01) | 1.39 (1.14–1.71, < 0.01) | 1.23 (1.05–1.72, < 0.01) | – |
Vasopressor use | – | 1.48 (1.04–2.12, 0.03) | 1.34 (1.05–1.65, 0.01) | 1.41 (1.19–1.69, < 0.01) |
Mechanical ventilation | – | 1.39 (1.09–2.12, < 0.01) | 1.38 (1.16–1.31, < 0.01) | 1.53 (1.33–1.73, < 0.01) |
Moderate anemia | – | – | – | – |
APACHE III score | 1.02 (1.02–1.03, < 0.01) | 1.02 (1.02–1.26, < 0.01) | 1.03 (1.02–1.04, < 0.01) | 1.03 (1.03–1.03, < 0.01) |
eGFR | – | – | 0.98 (0.98–0.99, < 0.01) | 0.98 (0.98–0.99, < 0.01) |
Hypotensive Index | 1.13 (1.04–1.24, < 0.01) | – | – | 1.04 (1.01–1.07, 0.01) |
ACE inhibitor/ARB | – | – | – | – |
Vancomycin | 1.46 (1.00–2.13, 0.04) | 1.56 (1.13–1.39, < 0.01) | 1.39 (1.08–1.77, 0.01) | 1.45 (1.18–1.77, < 0.01) |
Other antibiotics | – | – | – | – |
Calcineurin inhibitor | 2.72 (1.45–5.12, < 0.01) | – | 2.45 (1.59–3.75, < 0.01) | – |
NSAID | 0.51 (0.32–0.82, < 0.01) | 0.68 (0.49–0.80, 0.02) | 0.78 (0.63–0.96, 0.01) | 0.92 (0.80–1.07, 0.03) |
Other nephrotoxic medications | 1.60 (1.03–2.49, 0.03) | – | – | |
AUC (Q1–Q3) | 0.754 (0.732–0.776) | 0.769 (0.749–0.789) | 0.772 (0.757–0.787) | 0.770 (0.758–0.781) |